PA
INZY

Parallel Advisors’s Inozyme Pharma INZY Stock Holding History

Parallel Advisors’s Portfolio INZY Stock Details INZY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-16,457
Closed -$65.8K – 3624
2025
Q2 		$65.8K Hold
16,457
– – ﹤0.01% 1577
2025
Q1 		$15K Hold
16,457
– – ﹤0.01% 2274
2024
Q4 		$45.6K Hold
16,457
– – ﹤0.01% 1690
2024
Q3 		$86.1K Buy
16,457
+424
+3% +$2.2K ﹤0.01% 1340
2024
Q2 		$71.5K Hold
16,033
– – ﹤0.01% 1345
2024
Q1 		$123K Hold
16,033
– – ﹤0.01% 1081
2023
Q4 		$68.3K Buy
16,033
+406
+3% +$1.44K ﹤0.01% 1285
2023
Q3 		$65.6K Buy
15,627
+200
+1% +$1.02K ﹤0.01% 1261
2023
Q2 		$85.9K Sell
15,427
-4,440
-22% -$26.2K ﹤0.01% 1144
2023
Q1 		$114K Hold
19,867
– – ﹤0.01% 1000
2022
Q4 		$20.9K Buy
+19,867
New +$34.7K ﹤0.01% 1692

Parallel Advisors's INZY Position: Q3 2025 in Review

Parallel Advisors sold out of Inozyme Pharma (INZY) in Q3 2025, closing a stake of 16,457 shares — an estimated $65.8K sold.

Parallel Advisors first reported a position in INZY in Q4 2022 and held it in 11 quarters. The position peaked at $123K in Q1 2024. 0 funds tracked by Wall St. Rank hold INZY as of Q3 2025.

  • Parallel Advisors reported no remaining Inozyme Pharma position as of Q3 2025 after selling out during the quarter.
  • Parallel Advisors sold 16,457 Inozyme Pharma shares in Q3 2025, an estimated $65.8K.
  • Parallel Advisors first reported a position in Inozyme Pharma in Q4 2022 and held it in 11 quarters.
  • Parallel Advisors's Inozyme Pharma position peaked at $123K in Q1 2024.
  • 0 funds tracked by Wall St. Rank held Inozyme Pharma as of Q3 2025.

Based on Parallel Advisors's 13F filing for Q3 2025, filed 13 Nov 2025.